Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ciforadenant + daratumumab
- Development stage
- Unknown
- Lead developer
- Corvus Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**ciforadenant + daratumumab** is an investigational combination therapy being studied for treatment of relapsed or refractory multiple myeloma. Ciforadenant is a small molecule oral inhibitor of the adenosine-2A receptor (A2AR), which modulates the tumor microenvironment and enhances anti-tumor immune responses. Daratumumab is a monoclonal antibody targeting CD38, a protein expressed on myeloma cells, inducing cell death via multiple immune-mediated mechanisms. The combination is designed to leverage immune modulation (ciforadenant) and direct antibody targeting (daratumumab), potentially providing synergistic anti-myeloma effects. This regimen is currently under investigation in a Phase 1b open-label clinical trial for patients who have relapsed or refractory multiple myeloma[1][3][7].
- Other names
- CPI-444 + daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)ADORA2A (Adenosine A₂A Receptor)
Beyond the preview
Go deeper on ciforadenant + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ciforadenant + daratumumab.